Arima Genomics Partners with Active Motif for Hi-C Research Distribution
CARLSBAD, Calif., July 2, 2026 Arima Genomics, Inc. announced an exclusive distribution partnership with Active Motif Incorporated, granting the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CARLSBAD, Calif., July 2, 2026 Arima Genomics, Inc. announced an exclusive distribution partnership with Active Motif Incorporated, granting the...
PLYMOUTH MEETING, Pa., June 12, 2026 Braeburn has announced the presentation of new clinical and real-world research findings for...
SAN DIEGO, June 19, 2026 Fapon Biopharma and MOTE Therapeutics have announced plans to present their innovative dual-targeting, dual-platform...
BOSTON and ROLLE, Switzerland, June 19, 2026 SOPHiA GENETICS, a global leader in AI-driven precision medicine, has announced the...
BOSTON, June 12, 2026 Volta Labs, a leader in genomics workflow automation, has announced the launch of Twist Bioscience’s...
SALT LAKE CITY, Utah, June 8, 2026 Seek Labs announced a major milestone in antiviral research with the completion...
EVANSTON, Ill., June 2, 2026 Researchers at Endeavor Health have developed a groundbreaking genetic screening tool designed to provide...
SOUTH SAN FRANCISCO, California, May 27, 2026 Human Longevity, Inc. (HLI) has announced the creation of Human Life Foundation...
SINGAPORE, May 28, 2026 Gene Solutions announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device...
SALT LAKE CITY, May 26, 2026 Myriad Genetics announced the launch of Prolaris® + AI, the first prostate cancer...
